

[REDACTED]

---

**From:** [REDACTED] deloitte.co.uk>  
**Sent:** 03 February 2015 17:12  
**To:** Baumann Paul (NHS ENGLAND); Keogh Bruce (NHS ENGLAND); [REDACTED]  
**Cc:** [REDACTED]  
**Subject:** Follow-up from meeting with Simon Stevens  
**Follow Up Flag:** Follow up  
**Flag Status:** Completed

Dear all,

We thought the session with Simon Stevens was very helpful earlier – hope you all agree. I just wanted to follow-up by capturing the key questions and actions arising, so we can address in advance of us getting another session (hopefully) late next week.

We picked up five main questions:

1. What is the clinical case for seven day services, especially re mortality?
2. What is needed from pay negotiations to improve affordability?
3. What are the elements needed to deliver reductions in mortality?
4. Where have people done more or less to deliver 7DS, and what is the relationship with cost/benefits?
5. What is the impact of out-of-hospital services on A&E/NEL, and how significant is their impact?

Resulting actions (discussed briefly with Paul following the meeting):

- **Bruce** agreed to have mortality analysis from 2008 updated (Q1)
- Deloitte to break out some pay scenarios (Q2)
- Deloitte to run mortality bundle to show services needed to address mortality variation (Q3)
- NHSE/Deloitte to get NHSIQ detail on current implementation of 7DS and anything on cost – [REDACTED] – could you help by reaching out to [REDACTED] to get data from their self-assessment tool? (Q4)
- Deloitte to reach out to contacts delivering 7DS to gather any anecdotal data (Q4/Q5)
- Deloitte to show strength of evidence base for different benefits, including A&E/NEL (Q5)

Kind regards,

[REDACTED]

[REDACTED]

Deloitte MCS Limited

[REDACTED]

**IMPORTANT NOTICE**

This communication is from Deloitte LLP, a limited liability partnership registered in England and Wales with registered number OC303675. Its registered office is 2, New Street Square, London EC4A 3BZ, United Kingdom. Deloitte LLP is the United Kingdom member firm of Deloitte Touche Tohmatsu Limited (“DTTL”), a UK private company limited by guarantee, whose member firms are legally separate and independent entities. Please see [www.deloitte.co.uk/about](http://www.deloitte.co.uk/about) for a detailed description of the legal structure of DTTL and its member firms.

This communication contains information which is confidential and may also be privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s), please (1) notify [it.security.uk@deloitte.co.uk](mailto:it.security.uk@deloitte.co.uk) by forwarding this email and delete all copies from your system and (2) note that disclosure, distribution, copying or use of this communication is strictly prohibited. Email communications cannot be guaranteed to be secure or free from error or viruses. All emails sent to or from a Deloitte UK email account are securely archived and stored by an external supplier within the European Union.

To the extent permitted by law, Deloitte LLP does not accept any liability for use of or reliance on the contents of this email by any person save by the intended recipient(s) to the extent agreed in a Deloitte LLP engagement contract.

Opinions, conclusions and other information in this email which have not been delivered by way of the business of Deloitte LLP are neither given nor endorsed by it.